|
2 Companies |
|
1 Product |
|
1 Product |
|
0 Mechanisms of Action |
|
0 Trials |
|
4 News |
|
- Ilaris (canakinumab) / Novartis
Enrollment change, Trial withdrawal: Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease (clinicaltrials.gov) - Feb 17, 2017
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
N=26 --> 0 | Recruiting --> Withdrawn
- | Ilaris (canakinumab) / Novartis
Enrollment open: Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease (clinicaltrials.gov) - Dec 31, 2016
P2, N=26, Recruiting, Sponsor: Novartis Pharmaceuticals
N=26 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | Ilaris (canakinumab) / Novartis
New P2 trial: Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease (clinicaltrials.gov) - Dec 2, 2016
P2, N=26, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| clopidogrel / Generic mfg., clopidogrel/aspirin / Generic mfg.
New P4 trial: Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent (clinicaltrials.gov) - Apr 7, 2015
P4, N=448, Completed, Sponsor: Jeil Pharmaceutical Co., Ltd.